FutureWorld (FWDG) HempTech to Create HempTechRX with Advisory Board for CBD-based Pharmaceuticals & Nutraceuticals

CBD-Rich Hemp Oil for Wellness & Nutritional Markets


St. Petersburg, FL, March 18, 2014 (GLOBE NEWSWIRE) -- FutureWorld (OTCQB: FWDG), a U.S. Diversified Holding Company formed to capitalize on the burgeoning technology markets globally, announces today that it has created an advisory board for a new planned division called HempTechRX. The new division will concentrate on Cannabidiol (CBD) -based Pharmaceutical & Nutraceutical products for the wellness and nutritional supplement industry.

We believe the industrial hemp oil-based Cannabidiol (CBD) nutritional supplement, wellness and personal care products will become one of the biggest markets nationally. The global Nutraceutical market is projected to be in excess of $200 billion by 2015 and the current US Nutraceutical and Dietary supplement market is valued at around $42 billion. The infusion of the Cannabidiol (CBD) based products into this massive marketplace will create significant opportunities for legal marijuana and hemp based companies (and their shareholders) for the foreseeable future. HempTech through HempTechRX is engaging to be part of this significant opportunity.

Cannabinoids (non-psychoactive CBD) have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of a wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and auto-immune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and HIV dementia.

HempTechRX's formation of an advisory board will establish an operational, industry standard, division for Pharmaceutical & Nutraceutical grade products for the wellness and nutritional markets. HempTechRX's management team, through its association with PharmaX, will have extensive access to all the necessary information and resources to provide a sustainable and profitable pharmaceutical-grade division of HempTech.

About FutureWorld

FutureWorld (Other OTCQB: FWDG), a Delaware corporation, is a U.S. Diversified Holding Company, listed on the Over the Counter exchange, which was formed to capitalize on the burgeoning markets and technologies globally. FutureWorld, together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of burgeoning technologies, such as industrial Hemp, globally through HempTech. HempTech, a subsidiary of FutureWorld, is a technology division catered to the industrial Hemp market. HempTech provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation and consultation for the industrial hemp and legal medicinal marijuana. Our wireless agricultural smart sensor networks offers precision to the agriculture, irrigation systems, and greenhouses for the global Hemp industry. HempTech is also in development, production and marketing of industrial hemp and legal medicinal marijuana by-products throughout United States. To request further information about FutureWorld, please email us at investors@futureworldenergyinc.com or log onto our website at http://www.futureworldenergyinc.com

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions. 



            

Contact Data